Health Catalyst, Inc.
Health Catalyst, Inc. (HCAT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
hcat · stock forecast · 22 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 22 Wall Street analysts in the past 3 months
Buy
22 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$3.00
Consensus
$2.25
+28.6% upside
Low
$1.75
Median: $2 · Last Close: $1.75
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$2.25
28.6% upside
High Target
$3
71.4%
Low Target
$1.75
0.0%
Current Price
$1.75
as of today
Based on analyst price targets, the HCAT stock price prediction for the next 12 months ranges from $1.75 to $3. The consensus HCAT price forecast of $2.25 implies 28.6% upside from the current price of $1.75.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $1.75 | ↑ 0.00% |
1-day model range: $1.73–$1.77. Peak: $1.77 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · HCAT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-12 | Stephens & Co. | Maintains | Equal Weight→Equal Weight |
| 2026-03-18 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2026-03-13 | Cantor Fitzgerald | Maintains | Neutral→Neutral |
| 2026-03-13 | Stephens & Co. | Maintains | Equal Weight→Equal Weight |
| 2026-03-13 | Citigroup | Maintains | Neutral→Neutral |
| 2026-03-13 | Stifel | Maintains | Hold→Hold |
| 2026-03-13 | Canaccord Genuity | Maintains | Buy→Buy |
| 2026-01-09 | Citigroup | Maintains | Neutral→Neutral |
| 2025-11-11 | Stifel | Maintains | Hold→Hold |
| 2025-11-11 | Citigroup | Maintains | Neutral→Neutral |
Wall Street analysts have recently issued updated ratings on Health Catalyst, Inc. (HCAT) stock. Of the recent 146 rating actions, 8 were upgrades and 14 were downgrades. 22 analysts currently cover HCAT.
Analyst Recommendation Trends
HCAT analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$307M
↑ 16.5% YoY
Revenue Next Year
$310M
↑ 1.3% YoY
EPS This Year
$0.31
EPS Next Year
$0.20
↓ 36.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast HCAT EPS of $0.31 for the current fiscal year, based on estimates from 9 analysts. The HCAT revenue forecast is $307M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The HCAT stock forecast is supported by two independent data sources: analyst consensus ratings from 22 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HCAT price target is $2.25 (+28.6% upside), with an analyst consensus of Buy.
The HCAT short-term stock prediction for tomorrow is $1.75 (+0.00%).
Health Catalyst, Inc. trades on NASDAQ under the ticker HCAT. The HCAT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 55% of covering analysts.
Frequently asked questions
HCAT forecast · 8 questionsAccording to 22 Wall Street analysts, the average 12-month HCAT price target is $2.25, with a high forecast of $3.00 and a low of $1.75. The median price target is shown in the chart above when available. This implies +28.6% potential upside from the current price of $1.75.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.